Kennedy's peptide remark and the 2026 advisory review
This is one entry from the TitrateLab Vendor Graveyard, a dated archive of peptide-market shutdowns, buyer-loss reports and enforcement actions. Documented as February 27 – July 24, 2026. Evidence tier: Official or peer-reviewed record. Sources for this entry are linked inline below and annotated in the full Vendor Graveyard entry.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. said on The Joe Rogan Experience (#2461) that he expected an FDA announcement “within a couple of weeks”. A law firm’s summary of the episode reports him as saying FDA was expected to act in a way that could make about 14 peptides more accessible. What followed was narrower: FDA lifted 12 peptides from Category 2, put 7 to its advisory committee, and the committee recommended 6.
- April 15, 2026. FDA announced that after seven days it would remove 12 peptides from Category 2: BPC-157, KPV, TB-500, MOTs-C, emideltide, Semax, Epitalon, cathelicidin LL-37, dihexa acetate, GHK-Cu, mechano growth factor and Melanotan II. Removal “does not, in itself, establish eligibility for compounding under Section 503A.”
- April 16, 2026. A Federal Register notice (FR Doc 2026-07361, 91 FR 20465) scheduled the Pharmacy Compounding Advisory Committee for July 23-24, 2026 to consider seven of them for the 503A bulks list: BPC-157, KPV, TB-500 and MOTs-C on the first day, emideltide, Semax and Epitalon on the second.
- July 23-24, 2026. The committee recommended BPC-157, KPV and TB-500 (each 8-6, 1 abstention), MOTs-C (7-5, 2 abstentions), Semax (8-5, 1) and Epitalon (7-4, 1). It did not recommend emideltide (6-7, 1).
- Status on October 1, 2026. The vote is advisory. Adding a substance to the 503A bulks list requires FDA rulemaking. A Federal Register search on October 1, 2026 found no FDA proposed rule adding any of these substances.
Kennedy’s remark was not an agency action, and none of these steps “restored” Category 1 access. CJC-1295, AOD-9604 and thymosin alpha-1, often named in coverage of the remark, had already left Category 2 in September 2024 when their nominations were withdrawn, and were not among the 12 removed or the 7 reviewed in 2026; the committee had voted against all three on December 4, 2024 (see the Evexias / Farmakeio entry).
Evidence tier: Official or peer-reviewed record.
Sources: Federal Register 2026-07361, April 16, 2026; Goodwin, May 11, 2026; Orrick, April 16, 2026; McDermott Will & Schulte vote summary; Hyman, Phelps & McNamara FDA Law Blog, July 28, 2026; Frier Levitt, March 10, 2026.